Financial Daily from THE HINDU group of publications
Saturday, Dec 03, 2005


Group Sites

Corporate - Outlook

Asia Cryo-Cell plans 2 overseas banks

Our Bureau

The company would set up a stem cell transplant facility in Chennai in collaboration with a teaching hospital.

Bangalore , Dec. 2

ASIA Cryo-Cell Pvt Ltd, which provides cord blood stem cell banking service, has said it planned to set up two overseas banks for umbilical cord stem cells by June 2006.

It was considering Sri Lanka, Malaysia or Dubai as candidate locations.

The Chennai-based company, formed in November 2004, would soon set up a stem cell transplant facility in Chennai in collaboration with a teaching hospital there.

The unnamed hospital would offer therapies based on umbilical cord blood stem cells for leukaemia, neurological disorders, spinal cord injuries, diabetes and heart attack, said Mr S. Abhaya Kumar, Vice-Chairman and CEO of Asia Cryo-Cell, which markets its services under the LifeCell brand.

"We also want to bring in clinical trials (on stem cell based therapies) to the country and also announce a manufacturing partnership at an appropriate time," he told a news conference here.

Asia Cryo-Cell, along with like-minded bodies such as Manipal Acunova, is also trying to initiate an association of all agencies working on cord blood cells to ensure a healthy growth of the industry, Mr Abhaya Kumar said.

According to Mr Prasad Mangipudi, Vice-President (Marketing), the industry is poised for a major growth, to roughly Rs 1,000 crore in five years.

LifeCell, which has nearly 750 stem cell samples and some 1,000 enrolments from prospective parents from across the country, plans to add 16 collection centres to its current eight centres.

"We expect the enrolments to shoot up to 8,000 by the end of next year. Cord blood banking is still in a nascent stage in India," he said.

The Rs 14-crore Chennai centre can store one lakh stem cell samples for an initial fee of Rs 27,000 per sample.

The expansion plan will have an investment of Rs 60 crore over the next two years, to be funded through private equity, according to Mr Abhaya Kumar, who is also the Joint MD of Shasun Drugs & Chemicals Ltd.

Related Stories:
Asia CRYO-CELL to set up stem cell therapy centre

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

More Stories on : Outlook

Stories in this Section
Reliance cuts petro-chem prices

Toyota offers 1% interest on loans for Innova buyers
L&T bags order for Hyderabad airport terminal building
`Ranbaxy geared up to manufacture bird flu drug'
SREI Infrastructure launches two financial products
Telcon to invest Rs 200 cr for capacity expansion
Panyam stock split okayed
Radha Madhav Corpn plans IPO
Seshasayee Paper to seek shareholders' nod to enhance borrowing limit
BEML unveils Chinese-made wheel loader at Excon 2005
Sunstar to invest Rs 19 cr in 2 years
Clause 18 compliance — The form and substance
Reliance demerger case hearing adjourned
Grindwell Norton to buy bonded abrasives unit of Orient Abrasives
Damodar Valley Corpn's Bengal, Jharkhand power plant proposals hit snag
BG India, ONGC to operate 3 offshore deepwater blocks
Apollo Hospitals ties up with Johns Hopkins arm — To set up diagnostic lab in Hyderabad
ONGC to prepare investment blueprint to boost output
Asia Cryo-Cell plans 2 overseas banks
Swasti Power hopes to execute hydel project at Uttaranchal before time
Orchid's betalactam unit to yield Rs 270-cr sales
Tata Motors Nov sales up 9.1 pc
Subhash Chandra steps down as Zee Tele MD
New DuPont India President
Nish Patel takes over as MD of Alfa Laval India

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line